Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Russia's Sputnik V developers call on AstraZeneca to try combining vaccines

11/26/2020 | 02:11pm EST

MOSCOW, Nov 26 (Reuters) - Developers of the Sputnik V COVID-19 vaccine said on Thursday that AstraZeneca should try combining its experimental shot with the Russian one to boost efficacy.

Russia said its Sputnik V vaccine is 92% effective at protecting people from COVID-19, according to interim trial results, while AstraZeneca said its COVID-19 vaccine was 70% effective in pivotal trials and could be up to 90% effective.

"If they go for a new clinical trial, we suggest trying a regimen of combining the AZ shot with the #SputnikV human adenoviral vector shot to boost efficacy," the developers of the Russian vaccine said on their Twitter account.

"Combining vaccines may prove important for revaccinations."

AstraZeneca has said it will have as many as 200 million doses of its vaccine by the end of 2020.

The British developed vaccine is viewed as offering one of the best hopes for many developing countries because of its cheaper price and ability to be transported at normal fridge temperatures.

With 2,187,990 infections, Russia has the fourth-largest number of COVID-19 cases in the world behind the United States, India and Brazil.

AstraZeneca is likely to run an additional global trial to assess the efficacy of its vaccine, its chief executive Pascal Soriot was quoted as saying by Bloomberg News, after questions were raised over the results from its late-stage study.

The British government's Chief Scientific Adviser Patrick Vallance said the main point about the AstraZeneca vaccine was that it worked, when asked about these doubts.

"The headline result is the vaccine works and that's very exciting," Vallance said during a news briefing with British Prime Minister Boris Johnson.

(Reporting by Andrey Ostroukh; Editing by Alexander Smith)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.71% 7644 Delayed Quote.3.66%
EURO / BRAZILIAN REAL (EUR/BRL) -0.01% 6.3786 Delayed Quote.-0.49%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 0.63% 74.213 Delayed Quote.-0.74%
All news about ASTRAZENECA PLC
06:47aASTRAZENECA : Brazil to begin vaccination campaign on Monday afternoon
RE
06:06aHow Africa Is Leading From Behind in Global Coronavirus Vaccine Race
AQ
04:24aDAIICHI SANKYO : Enhertu approved in the US for the treatment of patients with p..
AQ
03:42aSouth Africa is promised 9 million J&J vaccine shots - Business Day
RE
03:16aVaccine manufacturing is lumpy, supply not as good as hoped, UK says
RE
02:24aASTRAZENECA : Brazil inoculates first citizens against COVID-19; grants 2 vaccin..
AQ
02:17aAstraZeneca's Enhertu Treatment for Metastatic Gastric Cancer Gains Approval ..
MT
01/17ASTRAZENECA : COVID-19 Vaccine Gains Emergency Use Approval in Pakistan
MT
01/17ASTRAZENECA : COVID-19 Vaccine Gets Emergency Use Approval in Brazil
MT
01/17ASTRAZENECA : Brazil Starts Its Covid-19 Vaccine Rollout -- 4th Update
DJ
More news
Financials (USD)
Sales 2020 26 400 M - -
Net income 2020 2 992 M - -
Net Debt 2020 13 217 M - -
P/E ratio 2020 43,0x
Yield 2020 2,73%
Capitalization 135 B 135 B -
EV / Sales 2020 5,63x
EV / Sales 2021 4,88x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 126,21 $
Last Close Price 103,14 $
Spread / Highest target 51,3%
Spread / Average Target 22,4%
Spread / Lowest Target -18,5%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC3.66%135 464
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993